Does Medicare Cover Mounjaro in 2026?

Direct Answer: When Does Medicare Cover Mounjaro in 2026?

It depends on your diagnosed condition. Medicare Part D covers Mounjaro (tirzepatide) when prescribed for type 2 diabetes, the FDA-approved indication for the Mounjaro brand. Medicare does not cover Mounjaro or Zepbound for obesity alone because the Social Security Act explicitly excludes weight-loss drugs from Part D. Zepbound carries one additional exception: Medicare Part D covers it for obstructive sleep apnea (OSA), where the FDA granted approval in December 2024.

What Original Medicare Covers for Tirzepatide (2026)

Original Medicare (Parts A and B) does not cover outpatient prescription drugs, including Mounjaro, unless administered in a clinical setting under Part B rules. Mounjaro is a self-injected pen that patients administer at home, so it falls under Part D (prescription drug coverage), not Part B (outpatient medical services).

Medicare Part D covers Mounjaro for type 2 diabetes when your plan includes it on the formulary. Most Part D plans place Mounjaro on tier 4 or tier 5 (specialty or non-preferred specialty) in 2026, which means out-of-pocket costs before reaching the annual cap can be significant. The 2026 Medicare Part D out-of-pocket cap is $2,100 per year, set by the Inflation Reduction Act of 2022. Once you hit that cap, your cost is $0 for the rest of the year.

Why Medicare Does Not Cover Mounjaro for Obesity (2026)

The Social Security Act Section 1927(d)(2)(A) prohibits Medicare Part D plans from covering drugs used for weight loss except in limited circumstances. This statutory exclusion predates GLP-1 drugs and was written when weight-loss drugs had poor efficacy and safety records. The law has not been amended to include modern GLP-1 agonists or dual GIP/GLP-1 agonists like tirzepatide.

Congress has considered legislation to allow Medicare coverage of obesity drugs. The TREAT and CMSS acts have been introduced in the House and Senate. Neither bill passed as of May 2026. If either passes, it would represent the first time Medicare covered drugs specifically for obesity, potentially extending coverage to Zepbound for weight management. Until then, the obesity-only exclusion stands for Part D plans.

The Zepbound Sleep Apnea Exception Explained (2026)

Zepbound (tirzepatide) received FDA approval in December 2024 as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity. Because obstructive sleep apnea is a respiratory condition, not a weight-loss indication, the Social Security Act's obesity-drug exclusion does not apply. Medicare Part D plans may cover Zepbound for that OSA indication in 2026.

Coverage is not guaranteed across all Part D plans. Each plan sets its own formulary, and Zepbound for OSA may require prior authorization and step therapy (typically requiring proof that CPAP or other standard OSA treatments were tried first). Check your 2026 plan formulary at Medicare.gov or call your plan's member services to confirm Zepbound coverage for sleep apnea specifically.

What Medicare Advantage May Add for Mounjaro (2026)

Medicare Advantage plans (Part C) must include the same drug coverage as Original Medicare Part D, but they have flexibility in how they set formulary tiers, cost-sharing, and prior authorization rules. Some Medicare Advantage plans in 2026 place Mounjaro on lower cost-sharing tiers for diabetes, lowering what you pay per fill. Some plans include supplemental drug benefits that go beyond standard Part D, but no Medicare Advantage plan is permitted to cover Mounjaro for obesity only, because the underlying Social Security Act exclusion applies to the entire Medicare program.

During Medicare's Annual Enrollment Period (October 15 through December 7, 2026), you can switch Medicare Advantage plans to find one with better Mounjaro tier placement for your diabetes diagnosis. Coverage under the new plan begins January 1, 2027. The Medicare Plan Finder at Medicare.gov lets you filter by drug name and enter Mounjaro to compare out-of-pocket costs across all available plans in your ZIP code.

Cost Without Medicare Coverage in 2026

Mounjaro without insurance costs approximately $1,000 to $1,100 per month at retail pharmacies in 2026 for a four-week supply. Zepbound has a similar price point. These costs vary by dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly injection pens) and by pharmacy.

LillyDirect is Eli Lilly's direct-to-patient pharmacy program. Patients who qualify for the self-pay option can access Mounjaro and Zepbound at reduced prices directly from LillyDirect. Important limitation: Medicare beneficiaries who use manufacturer savings cards or copay coupons for drugs covered under Part D may violate the federal anti-kickback statute. However, if Medicare does not cover the drug for your indication (for example, Zepbound for obesity only), you may be able to use LillyDirect self-pay pricing as a private-pay patient outside your Medicare coverage. Confirm with your plan and pharmacist before using any savings program.

How to Get Mounjaro Covered Under Medicare Part D in 2026

Medicare Part D coverage for Mounjaro requires four conditions to be met: you must be enrolled in a Part D plan (standalone PDP or Medicare Advantage with Part D), your plan must include Mounjaro on its 2026 formulary, your prescription must be for type 2 diabetes (not for weight management or obesity), and prior authorization requirements of your specific plan must be satisfied.

• Step 1: Confirm your diagnosis is documented as type 2 diabetes (ICD-10 code E11.x) in your medical record, not as obesity or overweight.
• Step 2: Search for plans that cover Mounjaro using the Medicare Plan Finder at Medicare.gov/plan-compare. Enter Mounjaro (or tirzepatide) in the drug search field.
• Step 3: If your plan requires prior authorization, your prescribing physician must submit clinical documentation including your A1C levels, diabetes diagnosis history, and any prior medications tried.
• Step 4: If prior authorization is denied, you have the right to appeal through your plan's internal appeals process within 60 days. A peer-to-peer review between your doctor and the plan's medical director often resolves denials.
• Step 5: During the Annual Enrollment Period (October 15 through December 7, 2026), consider switching to a Part D plan with lower tier placement for Mounjaro. Use Medicare Plan Finder to estimate your full-year out-of-pocket costs under each plan.

Alternatives If Medicare Does Not Cover Mounjaro for Your Situation

For people whose Medicare plan does not cover Mounjaro (most commonly, those with an obesity-only or weight-management diagnosis rather than type 2 diabetes), several alternatives exist in 2026.

• LillyDirect self-pay program: Eli Lilly offers Mounjaro and Zepbound at a set monthly self-pay price for patients paying out of pocket at LillyDirect.com. This option is available regardless of insurance status for patients who pay cash.
• Medicare Extra Help (Low Income Subsidy): If you qualify for Extra Help, your Part D cost-sharing is reduced significantly. For 2026, full Extra Help beneficiaries pay no more than $5.10 for generics and $12.65 for brand-name drugs per fill. Mounjaro is brand-name, so Extra Help reduces the cost substantially once you have a qualifying Part D plan that covers the drug.
• State Pharmaceutical Assistance Programs (SPAPs): Several states run programs that wrap around Medicare Part D and provide additional drug cost assistance. Contact your State Health Insurance Assistance Program (SHIP) at shiphelp.org to find out what state-level assistance exists for high-cost drugs.
• Other GLP-1 diabetes drugs with better Part D tier placement: Ozempic (semaglutide, FDA-approved for type 2 diabetes) and Trulicity (dulaglutide) are in the same GLP-1 drug class as Mounjaro and may have lower tier placement on some Part D plans. Ask your endocrinologist or primary care physician whether a formulary-preferred GLP-1 alternative could work for your diabetes management.
• Patient assistance programs: Eli Lilly offers Lilly Insulin Value Program and related assistance programs. Eligibility and availability vary; contact Lilly at 1-800-545-5979 or visit LillyAnswers.com to ask about assistance programs for Medicare patients.

Does Original Medicare cover Mounjaro?

Original Medicare (Parts A and B) does not cover outpatient prescription drugs, so it does not cover Mounjaro directly. Coverage comes from Medicare Part D (standalone drug plan) or a Medicare Advantage plan with Part D built in. With a qualifying Part D plan, Mounjaro is covered for type 2 diabetes only.

Does Medicare Part D cover Mounjaro for diabetes in 2026?

Yes, when your plan includes Mounjaro on its 2026 formulary and your prescription is for type 2 diabetes. Most plans place Mounjaro on tier 4 or tier 5 (specialty), so cost-sharing before reaching the $2,100 annual out-of-pocket cap (set by the Inflation Reduction Act of 2022) can be high. Use Medicare Plan Finder at Medicare.gov to compare plans by Mounjaro cost.

Does Medicare cover Zepbound for weight loss?

No. Medicare Part D cannot cover Zepbound (tirzepatide) for obesity or weight loss because the Social Security Act Section 1927(d)(2)(A) excludes weight-loss drugs from Part D. Zepbound is covered only for obstructive sleep apnea (OSA), which received FDA approval in December 2024. If you need Zepbound for weight management, you will need to pay out of pocket or use LillyDirect self-pay pricing.

Is Mounjaro the same as Zepbound?

Yes, both contain the same active ingredient, tirzepatide. Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes management (FDA-approved June 2022) and as Zepbound for obesity and obstructive sleep apnea. Medicare coverage rules treat them differently because the FDA approval indications differ, and the Social Security Act exclusion applies by indication, not by molecule.

What is the Medicare Part D out-of-pocket cap for Mounjaro in 2026?

The 2026 Medicare Part D out-of-pocket cap is $2,100, established by the Inflation Reduction Act of 2022. Once you pay $2,100 in covered drug costs in a calendar year, your cost for covered Part D drugs is $0 for the rest of the year. Mounjaro for diabetes is a covered Part D drug, so costs you pay for it count toward the $2,100 cap.

Can Medicare Advantage plans cover Mounjaro for obesity?

No. Medicare Advantage plans must follow the same Social Security Act restrictions as Original Medicare Part D. No Medicare Advantage plan is permitted to cover tirzepatide (Mounjaro or Zepbound) for obesity-only, because the statutory exclusion applies program-wide. Some Medicare Advantage plans may offer supplemental non-Medicare benefits through third-party arrangements, but weight-loss drug coverage through Medicare Advantage for obesity remains prohibited.

How much does Mounjaro cost without Medicare coverage in 2026?

Mounjaro costs approximately $1,000 to $1,100 per month at retail in 2026 depending on dose and pharmacy. Zepbound has a similar price point. LillyDirect offers a self-pay pricing program for patients paying out of pocket, with prices potentially lower than retail. Medicare beneficiaries typically cannot use manufacturer copay cards for drugs their plan covers, but may be able to use LillyDirect for non-covered indications.

Does Medicare Extra Help cover Mounjaro?

Extra Help (the Low Income Subsidy program) reduces Part D cost-sharing for qualifying low-income Medicare beneficiaries. In 2026, full Extra Help beneficiaries pay no more than $12.65 per fill for brand-name drugs like Mounjaro, once enrolled in a Part D plan that covers the drug for diabetes. Extra Help does not change the underlying coverage rule: Mounjaro must still be covered by your plan for your type 2 diabetes diagnosis.